Clinical TrialJul 13, 2026, 08:18 AM
Clearmind Medicine's CMND-100 shows positive early trial results
AI Summary
Clearmind Medicine Inc. announced positive early experiences from its ongoing Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic MEAI compound for Alcohol Use Disorder (AUD). Principal investigators from Yale and Johns Hopkins conveyed a generally positive impression, highlighting the compound's non-hallucinogenic profile, which could simplify treatment. The trial has shown a promising early safety profile with no meaningful adverse effects, and recruitment has progressed well.
Key Highlights
- Principal investigators highlighted positive early experience with CMND-100 in Phase I/IIa trial.
- MEAI's non-hallucinogenic profile allows for a simpler, more accessible treatment model.
- Recruitment for the trial has progressed well despite strict eligibility criteria.
- Promising early safety profile observed with no meaningful adverse effects or cardiac concerns.
- Study design, dose escalation, pharmacokinetics, and participant experience provided valuable insights.
- High potential for broader applications of MEAI beyond Alcohol Use Disorder (AUD).
Price Impact
More from CMND